ClinicalTrials.gg
Not yet recruitingNCT05650385Updated Dec 14, 2022

A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors

A Phase 1 interventional study of B1962 in Neoplasms Malignant, sponsored by Tasly Biopharmaceuticals Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-12-14.

Sponsored by Tasly Biopharmaceuticals Co., Ltd. (part of China Resources Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is to characterize the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of B1962, a PD-L1/VEGF bispecific antibody fusion protein, as a single agent in adult subjects with advanced solid tumor malignancies. The study consists of two parts: a once-weekly (QW) dosing phase and a biweekly (Q2W) dosing phase, which will explore the possibility of Q2W dosing of B1962 based on the PK data obtained in the QW phase. The study will determine the maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D) for B1962 as a single agent.

02

Conditions studied

  • Neoplasms Malignant

Browse trials for

03

In context

Neoplasms

10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's planned enrollment of 68 is above the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Tasly Biopharmaceuticals Co., Ltd. is the lead sponsor of 10 studies on the registry; 5 are open to participants now.

First submitted before Tasly Biopharmaceuticals Co., Ltd. became part of China Resources Pharmaceutical Group Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. written and signed .
  2. Age ≥ 18 years and ≤ 75 years at the time of signing the informed consent form.
  3. Patients with or cytologically confirmed advanced malignant solid tumors who have failed or failed to respond to standard therapy, or who are intolerant of standard therapy, or who have no standard effective treatment regimen, or who have refused standard therapy (posterior and endline).
  4. willing and able to comply with all study procedures.
  5. (ECOG) Performance Score of 0 or 1.
  6. ≥ 3 months.
  7. Subjects must have at least one according to Version 1.1
  8. Adequate organ and bone marrow function
  9. Females of and non-sterilized males who are sexually active must use an effective method of from screening until 120 days after final dose of product or women of non child bearing potential.

Exclusion criteria

Exclusion Criteria:

  1. Patients receiving (ICIs) or VEGF/VEGFR inhibitors within 28 days prior to the first dose of the study drug.
  2. Known allergy or reaction to any component of the B1962 formulation or history of severe reactions to other large protein agents/mAbs or BsAbs.
  3. Female patients who are pregnant or breastfeeding.
  4. Subjects has received major surgical procedure within 4 weeks prior to the first dose of B1962, or is scheduled to receive major surgical procedure during the current study period
  5. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to v5.0 Grade 0 or 1 (except for alopecia).
  6. Patients with untreated or clinically symptomatic , spinal cord compression, cancerous meningitis, or other evidence that the patient's brain or spinal cord have not been controlled (except in cases where the patient has been treated and has stable symptoms, imaging shows stability for at least 4 weeks prior to the first dose, and there is no evidence of brain edema and no need for therapies)
  7. Patients with clinically symptomatic or recurrent pleural effusions, pericardial effusions or ascites requiring repeated drainage
  8. Imaging at the screening period showed that the tumor was wrapped around important blood vessels or had significant necrosis or cavitiation, and the investigators judged that entering the study would cause bleeding risk
  9. Known history of infection or acquired immunodeficiency syndrome-related disease
  10. Patients with or C infection; or known active syphilis infection.
  11. Uncontrolled infections requiring systemic therapy within 4 weeks prior to the first dose of study drug.
  12. Subjects with cardiovascular disease; uncontrolled hypertension (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg) or poor compliance with antihypertensive therapy; major vascular disease.
  13. History of Coagulation disorders, bleeding disorders, or other conditions judged by the investigator to be a risk of bleeding within 6 months prior to the first dose.
  14. pulmonary hemorrhage/hemoptysis ≥ grade 2 (according to NCI-CTCAE v5.0) within 1 month prior to first drug administration
  15. or other minor surgery, excluding placement of vascular access devices, within 7 days prior to the first dose of B1962
  16. History of arterial or venous thrombosis, or stroke or within 6 months prior to the first dose of B1962
  17. Current unstable dose of anticoagulant or thrombolytic medication within 14 days of the first dose of B1962. Note: prophylactic use of low molecular heparin is acceptable.
  18. Aspirin (> 325 mg/day) or NSAIDs treatment within 14 days of first dose of B1962
  19. Uncontrolled diabetes mellitus ( >8%) on standard therapy
  20. Active or prior documented idiopathic pulmonary fibrosis or idiopathicpneumonia; current acute lung disease, interstitial lung disease or pneumonia (except localized interstitial pneumonia due to radiotherapy induction), pulmonary fibrosis, etc.; severe respiratory distress, pulmonary insufficiency or continuous oxygenation
  21. Active or prior documented of disease requiring systemic therapy within 2 years prior to screening. Note: Enrollment is permitted in the following conditions: hypothyroidism that can be controlled by hormone replacement therapy alone, skin conditions that do not require systemic therapy (e.g. vitiligo, psoriasis), and controlled celiac disease.
  22. Subjects with a condition requiring systemic treatment with either corticosteroid (> 10 mg daily ) or other medications within 14 days of first study drug administration (topical or physiological hormones dose is acceptable)
  23. Receipt of any systemic anticancer therapy within 4 weeks or 5 half-lives (whichever is longer) prior to first dose, small molecule tyrosine kinase-targeted agents therapy or immunomodulatory therapy within 2 weeks prior to first dose; or herbal or proprietary Chinese medicines with antitumor indications within 1 week prior to the first dose.
  24. For hepatocellular carcinoma: receipt of local area treatment of the liver within 4 weeks prior to the first dose of B1962
  25. History of organ or hematopoietic stem cell transplantation requiring immunosuppressive medications
  26. History of other neoplasms within 5 years prior to screening, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or cervical cancer in situ that has undergone successful radical surgery
  27. Received attenuated vaccination within 4 weeks prior to screening or planning to receive attenuated vaccination during the study period
  28. Patients who have participated in a clinical study and received study drug within 4 weeks or 5 half-lives (whichever is longer) prior to the first dose
  29. History of alcohol or drug abuse within 12 months prior to the first dose.
  30. Known history of psychiatric disorder that may affect trial compliance
  31. Other serious systemic disease, abnormal laboratory tests, or other reasons deemed inappropriate for subjects by the investigator
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    B1962 0.035mg Open Lable

    Drug: B1962

  • Experimental
    Cohort 2

    B1962 0.12mg Open Lable

    Drug: B1962

  • Experimental
    Cohort 3

    B1962 0.4mg Open Lable

    Drug: B1962

  • Experimental
    Cohort 4

    B1962 1.2mg Open Lable

    Drug: B1962

  • Experimental
    Cohort 5

    B1962 4mg Open Lable

    Drug: B1962

  • Experimental
    Cohort 6

    B1962 8mg Open Lable

    Drug: B1962

  • Experimental
    Cohort 7

    B1962 11mg Open Lable

    Drug: B1962

  • Experimental
    Cohort 8

    B1962 15mg Open Lable

    Drug: B1962

  • Experimental
    Cohort 9

    B1962 20mg Open Lable

    Drug: B1962

  • Experimental
    Cohort 10

    B1962 25mg Open Lable

    Drug: B1962

Interventions

06

What researchers measure

Primary outcomes

  1. DLT Assessment

    Toxicity associated with the treatment of the investigational drug B1962

    Time frame: From Day1 to Day15 after first dose of B1962

  2. AE Assessment

    The frequency of AE

    Time frame: From first dose of B1962 until 28 days after the last dose of B1962.

  3. 12-lead ECG Assessment

    Changes of 12-lead ECG from baseline

    Time frame: From first dose of B1962 until 28 days after the last dose of B1962.

  4. Eastern Cooperative Oncology Group score Assessment

    Changes of Eastern Cooperative Oncology Group score from baseline

    Time frame: From first dose of B1962 until 28 days after the last dose of B1962.

  5. Determine the maximum tolerated dose (MTD)

    Time frame: From first dose of B1962 until 28 days after the last dose of B1962

  6. Determine the recommended phase II dose (RP2D)

    Time frame: From first dose of B1962 until 28 days after the last dose of B1962

Secondary outcomes

  1. Peak Plasma Concentration (Cmax) Analysis

    Time frame: From first dose of B1962 through 7 days of deciding to stop research treatment by subjects

  2. Area under the plasma concentration versus time curve (AUC) Analysis

    Time frame: From first dose of B1962 through 7 days of deciding to stop research treatment by subjects

  3. Terminal elimination half-life(t1/2) Analysis

    Time frame: From first dose of B1962 through 7 days of deciding to stop research treatment by subjects

  4. Time to reach the maximum observed concentration(Tmax) Analysis

    Time frame: From first dose of B1962 through 7 days of deciding to stop research treatment by subjects

  5. Number of subjects who develop detectable anti-drug antibodies (ADAs)

    Time frame: From first dose of B1962 until 28 days after the last dose of B1962

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2022; primary completion for Dec 2023, 12 months later.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's planned 12 months is below that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2022
First posted
Dec 14, 2022
StartEst.
Dec 2022
Primary completionEst.
Dec 2023
CompletionEst.
Oct 2025
Last update
Dec 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05650385
Responsible party
Sponsor
First posted
Dec 14, 2022
Start date
Dec 2022 (estimated)
Primary completion
Dec 2023 (estimated)
Completion
Oct 2025 (estimated)
Last update
Dec 14, 2022

Study contacts

Kongli zhu, Master
Contact
tsl-zhukongli@tasly.com
+8615800363686
Kongli zhu, Master
study chair · Tasly Biopharmaceuticals Co., Ltd.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-L1/Anti-VEGF Bispecific Antibody AP505

Start the discussion